Leukocyte p53 protein biosignature through standard-aligned two-dimensional immunoblotting

Journal of Proteomics

Volumn 76, Issue , 2012, Pages 69-78

  Hjelle, Sigrun M ^a   Sulen, André ^a   Øye, Ola Kristoffer ^c   Jørgensen, Katarina ^a   McCormack, Emmet ^a   Hollund, Bjørg Eli ^a   Gjertsen, Bjørn Tore ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c CHRISTIAN MICHELSEN RESEARCH AS   (Norway)

Author keywords

2 DE; Alignment standard; Correlation analysis; Leukocytes; P53 isoforms; P53 and p53

Indexed keywords

PROTEIN P53; PROTEIN VARIANT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL STRESS; CONTROLLED STUDY; HUMAN; IMMUNOBLOTTING; LEUKOCYTE; MAJOR CLINICAL STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; COHORT STUDIES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES; MALE; MIDDLE AGED; PROTEIN ISOFORMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84869867283     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.07.021     Document Type: Article

References (48)

1. Liumbruno G., D'Alessandro A., Grazzini G., Zolla L. Blood-related proteomics. J. Proteomics 2010, 73:483-507.
2. Staratschek-Jox A., Classen S., Gaarz A., Debey-Pascher S., Schultze J.L. Blood-based transcriptomics: leukemias and beyond. Expert. Rev. Mol. Diagn. 2009, 9:271-280.
3. Maas K., Westfall M., Pietenpol J., Olsen N.J., Aune T. Reduced p53 in peripheral blood mononuclear cells from patients with rheumatoid arthritis is associated with loss of radiation-induced apoptosis. Arthritis Rheum. 2005, 52:1047-1057.
4. Mesko B., Poliska S., Nagy L. Gene expression profiles in peripheral blood for the diagnosis of autoimmune diseases. Trends Mol. Med. 2011, 17:223-233.
5. Mesko B., Poliska S., Szegedi A., Szekanecz Z., Palatka K., Papp M., et al. Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets. BMC Med. Genomics 2010, 3:15.
6. Wu G., Wang X., Feng X., Zhang A., Li J., Gu K., et al. Altered expression of autophagic genes in the peripheral leukocytes of patients with sporadic Parkinson's disease. Brain Res. 2011, 1394:105-111.
7. Timofeeva A.V., Goryunova L.E., Khaspekov G.L., Kovalevskii D.A., Scamrov A.V., Bulkina O.S., et al. Altered gene expression pattern in peripheral blood leukocytes from patients with arterial hypertension. Ann. N. Y. Acad. Sci. 2006, 1091:319-335.
8. Wu G., Wei G., Huang J., Pang S., Liu L., Yan B. Decreased gene expression of LC3 in peripheral leucocytes of patients with coronary artery disease. Eur. J. Clin. Invest. 2011, 41:958-963.
9. Mhyre T.R., Loy R., Tariot P.N., Profenno L.A., Maguire-Zeiss K.A., Zhang D., et al. Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium. Neurobiol. Aging 2008, 29:1631-1643.
10. Zhou X., Jia J. P53-mediated G(1)/S checkpoint dysfunction in lymphocytes from Alzheimer's disease patients. Neurosci. Lett. 2010, 468:320-325.
11. Kabacik S., Ortega-Molina A., Efeyan A., Finnon P., Bouffler S., Serrano M., et al. A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity. Cell Cycle 2011, 10:1152-1161.
12. Buizza L., Cenini G., Lanni C., Ferrari-Toninelli G., Prandelli C., Govoni S., et al. Conformational Altered p53 as an Early Marker of Oxidative Stress in Alzheimer's Disease. PLoS One 2012, 7:e29789.
13. Mayer C., Popanda O., Greve B., Fritz E., Illig T., Eckardt-Schupp F., et al. A radiation-induced gene expression signature as a tool to predict acute radiotherapy-induced adverse side effects. Cancer Lett. 2011, 302:20-28.
14. Anensen N., Haaland I., D'Santos C., Van Belle W., Gjertsen B.T. Proteomics of p53 in diagnostics and therapy of acute myeloid leukemia. Curr. Pharm. Biotechnol. 2006, 7:199-207.
15. Anensen N., Hjelle S.M., Van Belle W., Haaland I., Silden E., Bourdon J.C., et al. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene 2012, 31:1533-1545.
16. Anensen N., Oyan A.M., Bourdon J.C., Kalland K.H., Bruserud O., Gjertsen B.T. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clin. Cancer Res. 2006, 12:3985-3992.
17. Anensen N., Oyan A.M., Huseby S., Kalland K.H., Bruserud O., Gjertsen B.T. Early gene expression of acute myeloid leukemia in response to chemotherapy. Expert. Rev. Anticancer. Ther. 2007, 7:741-751.
18. Anensen N., Skavland J., Stapnes C., Ryningen A., Borresen-Dale A.L., Gjertsen B.T., et al. Acute myelogenous leukemia in a patient with Li-Fraumeni syndrome treated with valproic acid, theophyllamine and all-trans retinoic acid: a case report. Leukemia 2006, 20:734-736.
19. Cavalcanti G.B., Scheiner M.A., Simoes Magluta E.P., Vasconcelos F.C., Klumb C.E., Maia R.C. p53 flow cytometry evaluation in leukemias: correlation to factors affecting clinical outcome. Cytometry B Clin. Cytom. 2010, 78:253-259.
20. Irish J.M., Hovland R., Krutzik P.O., Perez O.D., Bruserud O., Gjertsen B.T., et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004, 118:217-228.
21. Mohr J., Helfrich H., Fuge M., Eldering E., Buhler A., Winkler D., et al. DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing. Blood 2011, 117:1622-1632.
22. Ociepa T., Maloney E., Kamienska E., Wysocki M., Kurylak A., Matysiak M., et al. Simultaneous assessment of p53 and MDM2 expression in leukemic cells in response to initial prednisone therapy in children with acute lymphoblastic leukemia. Pol. J. Pathol. 2010, 61:199-205.
23. Bourdon J.C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., Xirodimas D.P., et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 2005, 19:2122-2137.
24. Marcel V., Perrier S., Aoubala M., Ageorges S., Groves M.J., Diot A., et al. Delta160p53 is a novel N-terminal p53 isoform encoded by Delta133p53 transcript. FEBS Lett. 2010, 584:4463-4468.
25. Khoury M.P., Bourdon J.C. The isoforms of the p53 protein. Cold Spring Harb. Perspect. Biol. 2010, 2:a000927.
26. Marcel V., Dichtel-Danjoy M.L., Sagne C., Hafsi H., Ma D., Ortiz-Cuaran S., et al. Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ. 2011, 18:1815-1824.
27. Alban A., David S.O., Bjorkesten L., Andersson C., Sloge E., Lewis S., et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003, 3:36-44.
28. Hjelle S.M., Forthun R.B., Haaland I., Reikvam H., Sjoholt G., Bruserud O., et al. Clinical proteomics of myeloid leukemia. Genome Med. 2010, 2:41.
29. Chevallet M., Procaccio V., Rabilloud T. A nonradioactive double detection method for the assignment of spots in two-dimensional blots. Anal. Biochem. 1997, 251:69-72.
30. Noyce R.S., Collins S.E., Mossman K.L. Differential modification of interferon regulatory factor 3 following virus particle entry. J. Virol. 2009, 83:4013-4022.
31. Vettermann C., Jack H.M., Mielenz D. A colloidal silver staining-destaining method for precise assignment of immunoreactive spots in two-dimensional protein patterns. Anal. Biochem. 2002, 308:381-387.
32. Vogel J., Drapkin B., Oomen J., Beach D., Bloom K., Snyder M. Phosphorylation of gamma-tubulin regulates microtubule organization in budding yeast. Dev. Cell 2001, 1:621-631.
33. Wheelock A.M., Morin D., Bartosiewicz M., Buckpitt A.R. Use of a fluorescent internal protein standard to achieve quantitative two-dimensional gel electrophoresis. Proteomics 2006, 6:1385-1398.
34. Moen B.E., Norback D., Wieslander G., Bakke J.V., Mageroy N., Granslo J.T., et al. Can air pollution affect tear film stability? A cross-sectional study in the aftermath of an explosion accident. BMC Publ. Health 2011, 11:235.
35. Bruserud O., Hovland R., Wergeland L., Huang T.S., Gjertsen B.T. Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 2003, 88:416-428.
36. Palmer C., Diehn M., Alizadeh A.A., Brown P.O. Cell-type specific gene expression profiles of leukocytes in human peripheral blood. BMC Genomics 2006, 7:115.
37. Van Belle W., Anensen N., Haaland I., Bruserud O., Hogda K.A., Gjertsen B.T. Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. BMC Bioinforma. 2006, 7:198.
38. Wergeland L., Sjoholt G., Haaland I., Hovland R., Bruserud O., Gjertsen B.T. Pre-apoptotic response to therapeutic DNA damage involves protein modulation of Mcl-1, Hdm2 and Flt3 in acute myeloid leukemia cells. Mol. Cancer 2007, 6:33.
39. Gallagher R., Collins S., Trujillo J., McCredie K., Ahearn M., Tsai S., et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979, 54:713-733.
40. Abulencia A., Adelman J., Affolder T., Akimoto T., Albrow M.G., Ambrose D., et al. Observation of Bs(0)-Bs(0) oscillations. Phys. Rev. Lett. 2006, 97:242003.
41. Jungblut P., Eckerskorn C., Lottspeich F., Klose J. Blotting efficiency investigated by using two-dimensional electrophoresis, hydrophobic membranes and proteins from different sources. Electrophoresis 1990, 11:581-588.
42. Klose J. Protein mapping by combined isoelectric focusing and electrophoresis of mouse tissues. A novel approach to testing for induced point mutations in mammals. Humangenetik 1975, 26:231-243.
43. Klose J., Feller M. Two-dimensional electrophoresis of membrane and cytosol proteins of mouse liver and brain. Electrophoresis 1981, 2:12-24.
44. Reich N.C., Oren M., Levine A.J. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol. Cell. Biol. 1983, 3:2143-2150.
45. Reihsaus E., Kohler M., Kraiss S., Oren M., Montenarh M. Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. Oncogene 1990, 5:137-145.
46. Quintás-Cardama A., Yi H., Post S., Kornblau S. High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia 2011, ASH, San Diego.
47. Sellmann L., Carpinteiro A., Nuckel H., Scholtysik R., Siemer D., Klein-Hipass L., et al. p53 protein expression in chronic lymphocytic leukemia. Leuk. Lymphoma 2012, 53:1282-1288.
48. Whibley C., Pharoah P.D., Hollstein M. p53 polymorphisms: cancer implications. Nat. Rev. Cancer 2009, 9:95-107.